Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

When do minority drug-resistant HIV-1 variants have a major clinical impact?

Heneine W.

J Infect Dis. 2010 Mar;201(5):647-9. doi: 10.1086/650545. No abstract available.

PMID:
20102273
2.

Detection and significance of minority quasispecies of drug-resistant HIV-1.

Metzner KJ.

J HIV Ther. 2006 Dec;11(4):74-81. Review. No abstract available.

PMID:
17578210
3.

Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.

Ghosn J, Mazet AA, Avettand-Fenoel V, Peytavin G, Wirden M, Delfraissy JF, Chaix ML.

J Antimicrob Chemother. 2009 Aug;64(2):433-4. doi: 10.1093/jac/dkp182. Epub 2009 May 20. No abstract available.

PMID:
19457931
4.

Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.

Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A.

J Clin Virol. 2004 May;30(1):24-31.

PMID:
15072750
5.

HIV-1 drug resistance in variants from the female genital tract and plasma.

Kemal KS, Burger H, Mayers D, Anastos K, Foley B, Kitchen C, Huggins P, Schroeder T, Picchio G, Back S, Gao W, Meyer WA 3rd, Weiser B.

J Infect Dis. 2007 Feb 15;195(4):535-45. Epub 2007 Jan 8.

PMID:
17230413
6.

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.

Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort.

AIDS. 2008 Jul 31;22(12):1417-23. doi: 10.1097/QAD.0b013e3283034953.

7.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

PMID:
19210162
8.

Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.

Holguín A, Ramirez de Arellano E, Rivas P, Soriano V.

AIDS Rev. 2006 Apr-Jun;8(2):98-107. Review.

PMID:
16848277
9.

Transmission of HIV-1 variants resistant to the three classes of antiretroviral agents: implications for HIV therapy in primary infection.

Colson P, Ravaux I, Yahi N, Tourrès C, Gallais H, Tamalet C.

AIDS. 2002 Feb 15;16(3):507-9. No abstract available.

PMID:
11834974
10.

National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.

Delaugerre C, Flandre P, Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Schneider V, Yerly S, LeGoff J, Morand-Joubert L, Chaix ML, Costagliola D, Calvez V; NARS AC11 Resistance Group.

J Med Virol. 2008 May;80(5):762-5. doi: 10.1002/jmv.21158.

PMID:
18360911
11.

Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.

Bergroth T, Ekici H, Gisslén M, Loes SK, Goh LE, Freedman A, Lampe F, Johnson MA, Sönnerborg A.

J Med Virol. 2009 Jan;81(1):1-8. doi: 10.1002/jmv.21363.

PMID:
19031460
12.

Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.

Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, Duca P, Caramma I, Balotta C, Zazzi M.

Antivir Ther. 2006;11(3):329-34.

PMID:
16759049
13.

Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil.

Barreto CC, Nishyia A, Araújo LV, Ferreira JE, Busch MP, Sabino EC.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):338-41.

PMID:
16540943
14.

HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.

Simon VA; Aaron Diamond AIDS Research Center, New York, USA.

IAPAC Mon. 2001 Aug;7(8):235-7. No abstract available.

PMID:
11708276
15.

Evolution of HIV-1 in a patient population failing multiple-drug therapy.

Hong S, Cao J, Tu YT.

Microbiol Immunol. 2009 Sep;53(9):535-9. doi: 10.1111/j.1348-0421.2009.00153.x.

16.

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR.

J Virol. 2009 Feb;83(4):2038-43. doi: 10.1128/JVI.02154-08. Epub 2008 Nov 19.

17.

Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.

Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC.

Indian J Med Microbiol. 2009 Jul-Sep;27(3):231-6. doi: 10.4103/0255-0857.53205.

18.

Update of the drug resistance mutations in HIV-1: December 2009.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45. Review. No abstract available.

19.

[Evolution of HIV resistance mutations in the Valme referral center].

Nogales MC, Castro C, Martín-Mazuelos E.

Enferm Infecc Microbiol Clin. 2007 Feb;25(2):159. Spanish. No abstract available.

PMID:
17288915
20.

Transmission of zidovudine resistant strains of HIV-1: the first wave.

Blower S.

AIDS. 2001 Nov 23;15(17):2317-8. No abstract available.

PMID:
11698706

Supplemental Content

Support Center